USMLE Step 1 Complement System Disorders

Mastering the complement system is crucial for USMLE Step 1 not only because it’s a favorite target for exam writers, but because its disorders perfectly illustrate the link between foundational immunology and distinctive clinical presentations. Your ability to match a specific deficiency with its unique infection profile or autoimmune pattern can help you quickly narrow down answer choices in challenging vignettes.

Complement Pathway Fundamentals: Activation to Lysis

Before diving into deficiencies, you must have a clear mental map of the three activation pathways and their common lytic endpoint. Think of the complement system as a cascade of plasma proteins that, when triggered, rapidly amplifies a response to clear pathogens. The classical pathway is primarily activated by antigen-antibody (IgG or IgM) complexes. The lectin pathway is triggered by mannose-binding lectin binding directly to microbial sugars. The alternative pathway is spontaneously activated at a low level on pathogen surfaces and provides an antibody-independent first line of defense.

All three pathways converge at the cleavage of C3 into C3a and C3b. This is the most critical amplification step. C3b fragments coat the pathogen in a process called opsonization, marking it for phagocytosis. The cascades then proceed to cleave C5 into C5a and C5b. C5b initiates the formation of the membrane attack complex (MAC), which is composed of C5b, C6, C7, C8, and multiple C9 molecules. The MAC creates pores in the pathogen's membrane, leading to osmotic lysis. Anaphylatoxins C3a and C5a are potent mediators of inflammation and chemotaxis. Keeping this sequence straight is the first step to predicting the consequences when a part of it fails.

Deficiencies in Early Pathway Components: Autoimmunity and Angioedema

Deficiencies in early classical pathway components (C1, C2, C4) are strongly associated with autoimmune disease, particularly systemic lupus erythematosus (SLE). This is counterintuitive at first—why would a deficient immune component cause autoimmunity? The key is that these components are critical for clearing immune complexes and apoptotic debris. When C1q, for example, is deficient, apoptotic cells and self-antigens aren’t cleared properly, leading to a loss of self-tolerance and autoantibody production. On Step 1, a patient with a severe, early-onset SLE-like picture should prompt consideration of C1q deficiency.

A more classic, high-yield early component disorder is C1 inhibitor (C1 INH) deficiency, which causes hereditary angioedema. Clinical Vignette: A 25-year-old man presents with recurrent, non-pruritic, non-pitting swelling of the face and lips. He notes occasional episodes of severe abdominal pain. His symptoms are not responsive to antihistamines or epinephrine. Family history is positive for similar episodes. Here, the deficiency leads to unchecked activation of the classical pathway, consuming C2 and C4. The breakdown product of C2, a kinin-like molecule, causes increased vascular permeability and angioedema. Step 1 Strategy: The triad of non-responsive angioedema, abdominal pain, and a positive family history is pathognomonic. Lab findings will show low C4 (and low C2 during attacks), with a normal C1q level.

Deficiencies in Opsonization: C3 and Recurrent Infections

As the central convergence point of all three pathways, C3 is essential for effective opsonization and downstream lytic function. A deficiency in C3 or its regulatory factors (like Factor I or H) results in a severe susceptibility to recurrent pyogenic infections with encapsulated bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis. Without C3b to coat these bacteria, phagocytes cannot recognize and engulf them effectively. Clinical Vignette: An infant has a history of multiple severe episodes of pneumococcal pneumonia and meningococcal meningitis since birth. This profound, early-onset susceptibility to typical pyogenic organisms is the hallmark. Step 1 Strategy: When a vignette describes recurrent infections with pyogenic bacteria starting in infancy, think opsonization defect—either complement (C3) or antibody deficiency (e.g., Bruton's agammaglobulinemia).

Deficiencies in the Membrane Attack Complex: Selective Neisseria Susceptibility

Deficiencies in the terminal complement components (C5-C9) that form the MAC present with a very specific clinical picture: recurrent infections with Neisseria species only. Patients are uniquely susceptible to disseminated Neisseria meningitidis (meningococcemia) and Neisseria gonorrhoeae (disseminated gonococcal infection). The reason is that Neisseria bacteria are especially sensitive to complement-mediated lysis; other pathogens have alternative defenses. Clinical Vignette: A previously healthy 20-year-old college student survives an episode of fulminant meningococcemia. He later reports a prior history of disseminated gonococcal infection. This history is a massive clue. Step 1 Strategy: The keyword pairing is "recurrent Neisseria infections." The pathogen specificity is the differentiator from C3 deficiency, which causes broader pyogenic infections. These patients can also have a family history of similar infections.

Common Pitfalls

1. Confusing the infection profiles of C3 vs. terminal complement deficiencies. This is perhaps the most common trap. Remember: C3 deficiency → recurrent pyogenic infections (S. pneumoniae, H. influenzae) starting in infancy/childhood. Terminal MAC deficiency → recurrent Neisseria infections (meningitis, DGI) in otherwise healthy older children and adults. Drill this association.
2. Misunderstanding the mechanism of hereditary angioedema. Do not mistake it for a typical IgE-mediated allergic reaction. It is due to uncontrolled bradykinin production from C2 cleavage, not histamine. Therefore, it presents with non-pruritic swelling and is unresponsive to antihistamines, steroids, or epinephrine. Acute treatment is with C1 INH concentrate, ecallantide (kallikrein inhibitor), or icatibant (bradykinin receptor antagonist).
3. Overlooking C1q deficiency in autoimmune presentations. When an SLE vignette describes unusually severe disease or onset in very young patients, consider a complement deficiency. The lab clue is low C1q, whereas in typical SLE, C1q levels are normal (though C3 and C4 may be low due to consumption).
4. Forgetting the role of complement in clearing immune complexes. When asked why early classical component deficiencies cause SLE, the correct reasoning involves failure to clear immune complexes and apoptotic debris, not an inherent "overactive" immune state. This tests your mechanistic understanding beyond mere association.

Summary

• The complement system consists of three activation pathways (classical, lectin, alternative) that converge at C3, ultimately forming the membrane attack complex (MAC) for pathogen lysis.
• C1 inhibitor deficiency causes hereditary angioedema, characterized by non-responsive swelling and abdominal pain, with low C4 levels. Treatment is targeted at the bradykinin pathway.
• C3 deficiency leads to severe, recurrent pyogenic infections (e.g., S. pneumoniae) in infancy due to failed opsonization.
• Terminal complement (C5-C9) deficiency results in a selective susceptibility to recurrent Neisseria infections (meningitis, DGI), as these bacteria are uniquely sensitive to MAC lysis.
• Early classical component deficiencies (C1q, C2, C4) are strongly associated with SLE due to impaired clearance of immune complexes and apoptotic cells.
• For Step 1, focus on matching the clinical vignette's infection pattern (pyogenic vs. Neisseria) or autoimmune presentation to the specific deficient component's physiologic role.